ABC News: How AI is Shaping the Future of Drug Discovery
Phil Mounteney, VP at Dotmatics, explains in an ABC News interview how AI is rapidly transforming pharmaceutical R&D by accelerating drug discovery, lowering development costs, aiding in COVID-19 vaccine development, influencing FDA regulatory guidance, enhancing predictive capabilities in pharma, and how Dotmatics' Luma platform is driving this scientific intelligence revolution.
Artificial intelligence is changing the game in pharmaceutical R&D—and it's happening faster than most people think. In a recent interview with a California ABC News affiliate, Phil Mounteney, Vice President at Dotmatics, shares how AI is helping pharma companies accelerate drug discovery, reduce development costs, and bring safer, more effective treatments to patients, faster.
“If we can reduce the time and cost to bring a drug to market, we can get drugs to patients more quickly and affordably.” – Phil Mounteney, VP Science & Technology at Dotmatics
In this conversation, Phil also explains:
- How AI helped develop the COVID-19 vaccine
- Why the FDA is already incorporating AI into regulatory guidance
- How the pharma industry is becoming more predictive
- What the Luma platform is doing to power this transformation
Watch the full interview to see how Dotmatics is helping shape the future of medicine through scientific intelligence.
Related
AI’s Quiet Revolution is Accelerating Drug Discovery, Education and More
The Fast Company article discusses how AI is quietly revolutionizing industries like drug discovery and education by enabling faster, more efficient solutions that address global challenges, with Dotmatics offering personalized demos of their Luma platform to showcase AI capabilities in scientific research.
Fox News Charlotte: The Use of AI in Drug-making
Fox News Charlotte features Christian Olsen, Vice President of Biologics at Dotmatics, discussing how AI, particularly through the Dotmatics Luma platform, is revolutionizing pharmaceutical drug discovery by reducing costs and accelerating time to market while addressing complex research challenges in laboratories.
3 Customer Trends We’re Watching in 2025
In 2025, life science teams are prioritizing three key trends—Lab-in-a-Loop platforms that integrate instruments, data, workflows, and models to boost R&D efficiency; true multimodal discovery enabled by flexible informatics supporting diverse data types without fragmented tools; and Composite AI leveraging layered, governed, and traceable data across disciplines—all aimed at delivering tangible scientific innovation while addressing resource constraints and stringent AI governance requirements.
ABC News: How AI is Accelerating Drug Discovery
In an ABC News feature, Dotmatics VP Phil Mounteney explains how the company's AI-powered Luma platform accelerates drug discovery by transforming data into actionable insights, streamlining early-stage research, enhancing collaboration, and shortening preclinical timelines amid growing demand for connected, AI-ready data in life sciences.
Gray TV Washington DC: AI helping scientists make drug breakthroughs
The Gray TV Washington DC feature highlights how scientists, including Christian Olsen of Dotmatics, are leveraging AI and machine learning to accelerate drug discovery and expedite bringing new drugs to market.
Data Evolution in Pharma: The Spread of Multimodal
The pharmaceutical industry is shifting from single-mode to multimodal drug discovery, incorporating diverse therapeutic modalities like biologics, gene therapies, and small molecules, but this evolution presents significant challenges in integrating heterogeneous R&D data and technologies, necessitating advanced, compatible platforms to enable efficient collaboration and leverage AI-driven insights for faster, cost-effective drug development.